arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2021-27-2-133-145arthyper-1978Research ArticleСтатьиArticlesВлияние различных антигипертензивных препаратов на процессы сосудистого старенияThe impact of various antihypertensive medications on vascular aginghttps://orcid.org/0000-0001-7891-6850ДудинскаяЕ. Н.DudinskayaE. N.

Дудинская Екатерина Наильевна — кандидат медицинских наук, заведующая лабораторией возрастных метаболических и эндокринных нарушений ОСП «Российский геронтологический научно-клинический центр» ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России

ул. 1-я Леонова, д. 16, Москва, 129226

Ekaterina N. Dudinskaya, MD, PhD, Head, Laboratory of Agerelated Endocrine and Metabolic Diseases, Gerontology Research Centre

16 1-st Leonova street, Moscow, 129226 Russia

katharina.gin@gmail.comhttps://orcid.org/0000-0002-2028-3939МачехинаЛ. В.MatchekhinaL. V.

Мачехина Любовь Викторовна — кандидат медицинских наук, научный сотрудник лаборатории возрастных метаболических и эндокринных нарушений ОСП «Российский геронтологический научно-клинический центр» ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России

Москва

Lubov V. Matchekhina, MD, PhD, Research Fellow, Laboratory of Age-related Endocrine and Metabolic Diseases, Gerontology Reseacrh Centre

Moscow

mlv66@list.ruhttps://orcid.org/0000-0003-0048-268XЕруслановаК. А.EruslanovaK. A.

Ерусланова Ксения Алексеевна — научный сотрудник лаборатории сердечно-сосудистого старения ОСП «Российский геронтологический научно-клинический центр» ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России

Москва

Kseniya A. Eruslanova, MD, Junior Research Fellow, Laboratory of Cardiovascular Ageing, Gerontology Resaech Centre

Moscow

kae.07@mail.ruhttps://orcid.org/0000-0002-2349-8740ДоготарьО. А.DogotarO. A.

Доготарь Олеся Александровна — кандидат медицинских наук, доцент Центра симуляционного обучения Медицинского института ФГАОУ ВО РУДН

Москва

Olesia A. Dogotar, MD, PhD, Associate Professor, Medical Institute Simulation Training Center

Moscow

dogotar-oa@rudn.ruhttps://orcid.org/0000-0001-6153-360XРыльцеваЛ. П.RyltsevaL. P.

Рыльцева Лидия Павловна — студентка 4-го курса Медицинского института ФГАОУ ВО РУДН

Москва

Lidia P. Ryltseva, Student

Moscow

rylceva.lida@gmail.comhttps://orcid.org/0000-0003-0140-3509ЛызловаН. Ю.LyzlovaN. Yu.

Лызлова Наталия Юрьевна — студентка 4-го курса Медицинского института ФГАОУ ВО РУДН

Москва

Nataliya Y. Lyzlova, Student

Moscow

lyzlova.nataliya@mail.ruhttps://orcid.org/0000-0002-4089-3144ЩепинН. А.ShchepinN. A.

Щепин Николай Алексеевич — студент 4-го курса Медицинского института ФГАОУ ВО РУДН

Москва

Nickolay A. Shchepin, Student

Moscow

kolia.shchepin@yandex.ruhttps://orcid.org/0000-0002-1628-5093КотовскаяЮ. В.KotovskayaYu. V.

Котовская Юлия Викторовна — доктор медицинских наук, заместитель директора по научной работе ОСП «Российский геронтологический научно-клинический центр» ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России

Москва

Yuliya V. Kotovskaya, MD, PhD, DSc, Professor, Deputy Director, Gerontology Research Centre

Moscow

kotovskaya@bk.ruФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Medical Research UniversityRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»РоссияRUDN UniversityRussian Federation202128122020272133145Copyright © Дудинская Е.Н., Мачехина Л.В., Ерусланова К.А., Доготарь О.А., Рыльцева Л.П., Лызлова Н.Ю., Щепин Н.А., Котовская Ю.В., 20212021Дудинская Е.Н., Мачехина Л.В., Ерусланова К.А., Доготарь О.А., Рыльцева Л.П., Лызлова Н.Ю., Щепин Н.А., Котовская Ю.В.Dudinskaya E.N., Matchekhina L.V., Eruslanova K.A., Dogotar O.A., Ryltseva L.P., Lyzlova N.Y., Shchepin N.A., Kotovskaya Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1978

В обзоре суммированы данные за последние два десятилетия о влиянии артериальной гипертензии на старение сосудистой стенки, рассмотрены контуры воздействия хронического воспаления и окислительного стресса на ремоделирование сердечно-сосудистой системы. Статья посвящена анализу данных клинических исследований о действии различных классов антигипертензивных препаратов на возраст-ассоциированные параметры старения слоев стенки артериальных сосудов, такие как эндотелиальная дисфункция, артериальная ригидность, которые оценивались с помощью показателей эндотелийзависимой вазодилатации, скорости пульсовой волны, индекса аугментации, сердечно-лодыжечного сосудистого индекса, толщины комплекса интима-медиа и так далее.

The review summarizes the data of past two decades on the effect of hypertension on vascular aging and considers the effect of chronic inflammation and oxidative stress patterns on the remodeling of cardiovascular system. Clinical studies on the effect of various classes of antihypertensive drugs on age-associated parameters of vascular aging are discussed. These include endothelial dysfunction and arterial assessed by endothelium-dependent vasodilation, pulse wave velocity, augmentation index, cardiovascular index, thickness of the intima-media complex, and so on.

артериальная гипертензиясосудистое старениескорость распространения пульсовой волныжесткость артерийhypertensionvascular ageingpulse wave velocityarterial stiffnessReferencesGBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi:10.1016/S0140-6736(14)61682-2GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi:10.1016/S0140-6736(14)61682-2Кобалава Ж. Д., Конради А. О., Недогода С. В., Шляхто Е. В., Арутюнов Г. П., Баранова Е. И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786.Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. In Russian.Демографический ежегодник России. 2019. Стат. сб. Росстат. М. 2019. 263 с.The Demographic Yearbook of Russia. Rosstat. M. 2019. 263 p. In Russian.Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. Curr Opin Cardiol. 2010;25(4):394–398. doi:10.1097/hco.0b013e328338c109Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. Curr Opin Cardiol. 2010;25(4):394–398. doi:10.1097/hco.0b013e328338c109Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327. doi:10.1016/j.jacc.2009.10.061Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327. doi:10.1016/j.jacc.2009.10.061Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57(3):363–369. doi:10.1161/HYPERTENSIONAHA.110.167015Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57(3):363–369. doi:10.1161/HYPERTENSIONAHA.110.167015Стражеско И. Д., Ткачева О. Н., Акашева Д. У., Дудинская Е. Н., Агальцов М. В., Кругликова А. С. и др. Взаимосвязь между различными структурно-функциональными характеристиками состояния артериальной стенки и традиционными факторами кардиоваскулярного риска у здоровых людей разного возраста. Часть 2. Рациональная фармакотерапия в кардиологии. 2016;12(3):244–252.Strazhesko ID, Tkacheva ON, Akasheva DU, Dudinskaya EV, Agaltsov MV, Kruglikova AS et al. Correlations of different structural and functional characteristics of arterial wall with traditional cardiovascular risk factors in healthy people of different age. Part 2. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2016;12(3):244–252. In Russian.Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S, Reference Values for Arterial Measurements Collaboration. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J. 2013;34(30):2368–2380. doi:10.1093/eurheartj/ehs380Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S, Reference Values for Arterial Measurements Collaboration. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J. 2013;34(30):2368–2380. doi:10.1093/eurheartj/ehs380Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116(6):1007–1021. doi:10.1161/CIRCRESAHA.116.303596Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116(6):1007–1021. doi:10.1161/CIRCRESAHA.116.303596Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension. 2005;45(6):1050–1055. doi:10.1161/01.HYP.0000164580.39991.3dLaurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension. 2005;45(6):1050–1055. doi:10.1161/01.HYP.0000164580.39991.3dNilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31(8):1517–1526. doi:10.1097/HJH.0b013e328361e4bdNilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31(8):1517–1526. doi:10.1097/HJH.0b013e328361e4bdLaslett LJ, Alagona P, Clark BA, Drozфda JP, Saldivar F, Wilson SR et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S 1–S 49. doi:10.1016/j.jacc.2012.11.002Laslett LJ, Alagona P, Clark BA, Drozфda JP, Saldivar F, Wilson SR et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S 1–S 49. doi:10.1016/j.jacc.2012.11.002Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54(1):3–10. doi:10.1161/HYPERTENSIONAHA.109.129114Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54(1):3–10. doi:10.1161/HYPERTENSIONAHA.109.129114Mitchell GF. Arterial stiffness and wave reflection: biomarkers of cardiovascular risk. Artery Res. 2009;3(2):56–64. doi:10.1016/j.artres.2009.02.002Mitchell GF. Arterial stiffness and wave reflection: biomarkers of cardiovascular risk. Artery Res. 2009;3(2):56–64. doi:10.1016/j.artres.2009.02.002Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43(6):1239–1245. doi:10.1161/01.HYP.0000128420.01881.aaMitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43(6):1239–1245. doi:10.1161/01.HYP.0000128420.01881.aaNajjar SS, Scuteri A, Shetty V, Wright JG, Muller DC, Fleg JL et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2008;51(14):1377–1383. doi:10.1016/j.jacc.2007.10.065Najjar SS, Scuteri A, Shetty V, Wright JG, Muller DC, Fleg JL et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2008;51(14):1377–1383. doi:10.1016/j.jacc.2007.10.065Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int. 2001;59(5):1834–1841. doi:10.1046/j.1523-1755.2001.0590051834.xMourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int. 2001;59(5):1834–1841. doi:10.1046/j.1523-1755.2001.0590051834.xAgabiti-Rosei E, Mancia G, O’Rourke MF, Roman MJ, Safar ME, Smulyan H et al. Central blood pressure measurements and antihypertensive therapy a consensus document. Hypertension. 2007;50(1):154–160. doi:10.1161/HYPERTENSIONAHA.107.090068Agabiti-Rosei E, Mancia G, O’Rourke MF, Roman MJ, Safar ME, Smulyan H et al. Central blood pressure measurements and antihypertensive therapy a consensus document. Hypertension. 2007;50(1):154–160. doi:10.1161/HYPERTENSIONAHA.107.090068Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci (Lond). 2010;119(4):151–161. doi:10.1042/CS20090544Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci (Lond). 2010;119(4):151–161. doi:10.1042/CS20090544Falkner B. Hypertension in children and adolescents: epidemiology and natural history. Pediatr Nephrol. 2010;25(7):1219–1224. doi:10.1007/s00467-009-1200-3Falkner B. Hypertension in children and adolescents: epidemiology and natural history. Pediatr Nephrol. 2010;25(7):1219–1224. doi:10.1007/s00467-009-1200-3Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Seidell JC, Stehouwer CD. Current and adolescent body fatness and fat distribution: relationships with carotid intima-media thickness and large artery stiffness at the age of 36 years. J Hypertens. 2004;22(1):145–155. doi:10.1097/00004872-200401000-00024Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Seidell JC, Stehouwer CD. Current and adolescent body fatness and fat distribution: relationships with carotid intima-media thickness and large artery stiffness at the age of 36 years. J Hypertens. 2004;22(1):145–155. doi:10.1097/00004872-200401000-00024Petersen KS, Blanch N, Keogh JB, Clifton PM. Effect of weight loss on pulse wave velocity: systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2015;35(1):243–252. doi:10.1161/ATVBAHA.114.304798Petersen KS, Blanch N, Keogh JB, Clifton PM. Effect of weight loss on pulse wave velocity: systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2015;35(1):243–252. doi:10.1161/ATVBAHA.114.304798Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41(6):1281–1286. doi:10.1161/01.HYP.0000070956.57418.22Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41(6):1281–1286. doi:10.1161/01.HYP.0000070956.57418.22Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16(5):309–321. doi:10.1007/s40256-016-0173-4.Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16(5):309–321. doi:10.1007/s40256-016-0173-4.Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther. 2007;21(6):423–429. doi:10.1007/s10557-007-6068-5Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther. 2007;21(6):423–429. doi:10.1007/s10557-007-6068-5Сиренко Ю. Н., Рековец О. Л., Кушнир С. Н., Торбас Е. Сравнительная эффективность эналаприла и периндоприла по влиянию на центральное артериальное давление и упруго-эластические свойства артерий у пациентов с мягкой и умеренной артериальной гипертензией. Артериальная гипертензия. 2016;2(46):101–112.Sirenko JuN, Rekovec OL, Kushnir SN, Torbas E. Comparative efficiency of enalapril and perindopril in terms of the effect on central blood pressure and elastic properties of arteries in patients with mild to moderate hypertension. Arterial’naya Gipertenziya = Arterial Hypertension. 2016;2(46):101–112. In Russian.Недогода С. В., Палашкин Р. В., Ледяева А. А., Чумачек Е. В., Смирнова В. О., Хрипаева В. Ю. Предупреждение раннего сосудистого старения при ожирении на фоне терапии ингибиторами ангиотензинпревращающего фермента. Доктор. Ру. 2016;11(128):5–9.Nedogoda SV, Palashkin RV, Ledjaeva AA, Chumachyok EV, Smirnova VO, Khripaeva VYu. Preventing early vascular aging in obese patients who are receiving angiotensin-converting enzyme inhibitors. Doсtor.Ru. 2016;11(128):5–9. In Russian.Стражеско И. Д. Возраст-ассоциированные изменения артериальной стенки: взаимосвязь с гормонально-метаболическим статусом и биологией теломер. Дис. … д-ра мед. наук. М., 2019. URL: https://www.dissercat.com/content/vozrast-assotsiirovannye-izmeneniya-arterialnoi-stenki-vzaimosvyaz-s-gormonalno-metaboliches.Strazhesko ID. Age-associated changes in the arterial wall: relationship with hormonal-metabolic status and telomere biology. [PhD thesis]. M., 2019. URL: https://www.dissercat.com/content/vozrast-assotsiirovannye-izmeneniya-arterialnoi-stenki-vzaimosvyaz-s-gormonalno-metaboliches In Russian.Tropeano AI, Boutouyrie P, Pannier B,Joannides R, Balkestein E, Katsahian S et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80–86. doi:10.1161/01.HYP.0000224283.76347.8cTropeano AI, Boutouyrie P, Pannier B,Joannides R, Balkestein E, Katsahian S et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80–86. doi:10.1161/01.HYP.0000224283.76347.8cRodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, Winter S, Ligthart JMR et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). Am J Cardiol. 2007;100(2):159–163. doi:10.1016/j.amjcard.2007.02.073Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, Winter S, Ligthart JMR et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). Am J Cardiol. 2007;100(2):159–163. doi:10.1016/j.amjcard.2007.02.073Bruining N, de Winter S, Roelandt JR, Rodriguez-Granillo GA, Heller I, van Domburg RT et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis. 2009;20(6):409–414. doi:10.1097/MCA.0b013e32832fa9b8Bruining N, de Winter S, Roelandt JR, Rodriguez-Granillo GA, Heller I, van Domburg RT et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis. 2009;20(6):409–414. doi:10.1097/MCA.0b013e32832fa9b8Bots ML, Remme WJ, Lüscher TF, Fox KM, Bertrand M, Ferrari R et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther. 2007;21(4):269–279. doi:10.1007/s10557-007-6041-3Bots ML, Remme WJ, Lüscher TF, Fox KM, Bertrand M, Ferrari R et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther. 2007;21(4):269–279. doi:10.1007/s10557-007-6041-3Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–246. doi:10.1016/j.cardiores.2006.10.021Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–246. doi:10.1016/j.cardiores.2006.10.021You D, Cochain C, Loinard C, Vilar J, Mees B, Duriez M et al. Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. Hypertension. 2008;51(6):1537–1544. doi:10.1161/HYPERTENSIONAHA.107.109066You D, Cochain C, Loinard C, Vilar J, Mees B, Duriez M et al. Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. Hypertension. 2008;51(6):1537–1544. doi:10.1161/HYPERTENSIONAHA.107.109066Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35(1):60–66. doi:10.1016/s0735-1097(99)00537-9Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35(1):60–66. doi:10.1016/s0735-1097(99)00537-9De Gennaro Colonna V, Rossoni G, Rigamonti A, Bonomo S, Manfredi B, Berti F et al. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol. 2002;450(1):61–6. doi:10.1016/S0014-2999(02)02046-0De Gennaro Colonna V, Rossoni G, Rigamonti A, Bonomo S, Manfredi B, Berti F et al. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol. 2002;450(1):61–6. doi:10.1016/S0014-2999(02)02046-0Леонова М. В., Демидова М. А., Тарасов А. В., Белоусов Ю. Б. Гипотензивная, органопротективная и метаболическая эффективность спираприла у больных артериальной гипертензией. Рациональная фармакотерапия в кардиологии. 2005;1(2):4–8.Leonova MV, Demidova MA, Tarasov AV, Belousov Ju B. Antihypertensive, organoprotective and metabolic efficacy of Spirapril in hypertensive patients. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2005;1(2):4–8. In Russian.Олейников В. Э., Матросова И. Б., Томашевская Ю. А., Герасимова А. С. Влияние ингибитора АПФ квадроприла на структурно-функциональные свойства сосудистой стенки при метаболическом синдроме и эссенциальной гипертонии. Российский кардиологический журнал. 2006;58(2):36–41.Olejnikov VJe, Matrosova IB, Tomashevskaja JuA, Gerasimova AS. The impact of ACE inhibitor Quadropril on structural and functional properties of vascular wall in metabolic syndrome and essential hypertension. Russian Journal of Cardiology. 2006;58(2):36–41. In Russian.Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of vascular aging. Circ Res. 2018;123(7):849–867. doi:10.1161/CIRCRESAHA.118.311378Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of vascular aging. Circ Res. 2018;123(7):849–867. doi:10.1161/CIRCRESAHA.118.311378Подзолков В. И., Писарев М. В., Затейщикова Д. А. Блокаторы ангиотензиновых рецепторов: рациональный выбор с учетом влияния на кардиоваскулярный риск и сопутствующие заболевания. Российский кардиологический журнал. 2018;(11):89–95. doi:10.15829/1560-4071-2018-11-89-95Podzolkov VI, Pisarev MV, Zateyshchikova DA. Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities. Russian Journal of Cardiology. 2018;(11):89–95. doi:10.15829/1560-4071-2018-11-89-95. In Russian.Недогода С. В. PPAR-γ-активация — ключевое преимущество телмисартана и его комбинаций. Атмосфера. Новости кардиологии. 2016;1.Nedogoda SV. PPAR-γ-activation is a key benefit of telmisartan and its combinations. Atmosphere. Novosti Kardiologii = Cardiology news. 2016;1. In Russian.Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial [published correction appears in Lancet. 2008;372(9647):1384]. Lancet. 2008;372(9644):1174–1183. doi:10.1016/S0140-6736(08)61242-8Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial [published correction appears in Lancet. 2008;372(9647):1384]. Lancet. 2008;372(9644):1174–1183. doi:10.1016/S0140-6736(08)61242-8Flavahan S, Chang F, Flavahan NA. Local renin-angiotensin system mediates endothelial dilator dysfunction in aging arteries. Am J Physiol Heart Circ Physiol. 2016;311(3): H849-H854. doi:10.1152/ajpheart.00422.2016Flavahan S, Chang F, Flavahan NA. Local renin-angiotensin system mediates endothelial dilator dysfunction in aging arteries. Am J Physiol Heart Circ Physiol. 2016;311(3): H849-H854. doi:10.1152/ajpheart.00422.2016Яковлева М. В., Прибылов С. А., Прибылова Н. Н. Влияние ИАПФ, сартанов и хирургической реваскуляризации на жесткость сосудистой стенки у больных ишемической болезнью сердца в сочетании с хронической болезнью почек. Курский научно-практический вестник «Человек и его здоровье». 2019;(3):12–19. doi:10.21626/vestnik/2019-3/02Yakovleva MV, Pribylov SA, Pribylova NN. Effect of ACE inhibitors, sartans and surgical revascularization on the rigidity of the vascular wall in patients with coronary heart disease in combination with chronic kidney disease. Kyrskiy Nauchno-prakticheskiy Vestnik “Chelovek I ego Zdorovie” = Kursk Scientific and Practical Bulletin “Man and his health”. 2019;(3):12–19. doi:10.21626/vestnik/2019–3/02. In Russian.Janić M, Lunder M, Novaković S, Škerl P, Šabovič M. Expression of longevity genes induced by a low-dose fluvastatin and valsartan combination with the potential to prevent/treat “Aging-Related Disorders”. Int J Mol Sci. 2019;20(8):1844. doi:10.3390/ijms20081844Janić M, Lunder M, Novaković S, Škerl P, Šabovič M. Expression of longevity genes induced by a low-dose fluvastatin and valsartan combination with the potential to prevent/treat “Aging-Related Disorders”. Int J Mol Sci. 2019;20(8):1844. doi:10.3390/ijms20081844Shan H, Zhang S, Li X, Yu K, Zhao X, Chen X et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014;18(6):1071–1080. doi:10.1111/jcmm.12251Shan H, Zhang S, Li X, Yu K, Zhao X, Chen X et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014;18(6):1071–1080. doi:10.1111/jcmm.12251Lunder M, Janic M, Sabovic M. Reduction of age-associated arterial wall changes by low-dose valsartan. Eur J Prev Cardiol. 2012;19(6):1243–1249. doi:10.1177/1741826711423104Lunder M, Janic M, Sabovic M. Reduction of age-associated arterial wall changes by low-dose valsartan. Eur J Prev Cardiol. 2012;19(6):1243–1249. doi:10.1177/1741826711423104Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104(5):511–514. doi:10.1161/hc3001.094207Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104(5):511–514. doi:10.1161/hc3001.094207Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111(5): 309–316. doi:10.1111/j.1742-7843.2012.00911.xZepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111(5): 309–316. doi:10.1111/j.1742-7843.2012.00911.xПристром А. М., Гайшун Е. И. Влияние β-адреноблокаторов на растяжимость и эластичность общей сонной артерии пациентов с хронической ишемической болезнью сердца, перенесших интракоронарное стентирование. Медицинские новости. 2012;6.Pristrom AM, Gaishun EI. Effect of β-blockers on the extensibility and elasticity of the common carotid artery in patients with chronic ischemic heart disease who underwent intracoronary stenting. Meditsinskiye Novosti = Medical News. 2012;6. In Russian.Kelly AS, Gonzalez-Campoy JM, Rudser KD, Katz H, Metzig AM, Thalin M et al. Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. J Clin Hypertens (Greenwich). 2012;14(2):85–91. doi:10.1111/j.1751-7176.2011.00569.xKelly AS, Gonzalez-Campoy JM, Rudser KD, Katz H, Metzig AM, Thalin M et al. Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. J Clin Hypertens (Greenwich). 2012;14(2):85–91. doi:10.1111/j.1751-7176.2011.00569.xОлейников В. Э., Матросова И. Б., Томашевская Ю. А., Гусаковская Л. И., Мельникова Е. А. Влияние терапии метопрололом на артериальную ригидность. Рациональная фармакотерапия в кардиологии. 2011;7(6):685–689. doi:10.20996/1819-6446-2011-7-6-685-689Oleynikov VE, Matrosova IB, Tomashevskaya YA, Gusakovskaya LI, Melnikova EA. Effect of metoprolol therapy on the arterial stiffness. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2011;7(6): 685–689. In Russian.Majidinia M, Rasmi Y, Khadem Ansari MH, Seyed-Mohammadzad M, Saboory E, Shirpoor A. Metoprolol improves endothelial function in patients with cardiac syndrome X. Iran J Pharm Res. 2016;15(3):561–566.Majidinia M, Rasmi Y, Khadem Ansari MH, Seyed-Mohammadzad M, Saboory E, Shirpoor A. Metoprolol improves endothelial function in patients with cardiac syndrome X. Iran J Pharm Res. 2016;15(3):561–566.Stauffer BL, Dow CA, Diehl KJ, Bammert TD, Greiner JJ, DeSouza CA. Nebivolol, but not metoprolol, treatment improves endothelial fibrinolytic capacity in adults with elevated blood pressure. J Am Heart Assoc. 2017;6(11):e007437. doi:10.1161/JAHA.117.007437Stauffer BL, Dow CA, Diehl KJ, Bammert TD, Greiner JJ, DeSouza CA. Nebivolol, but not metoprolol, treatment improves endothelial fibrinolytic capacity in adults with elevated blood pressure. J Am Heart Assoc. 2017;6(11):e007437. doi:10.1161/JAHA.117.007437Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103(13):1721–1726. doi:10.1161/01.cir.103.13.1721Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103(13):1721–1726. doi:10.1161/01.cir.103.13.1721Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33(2):572–577. doi:10.1161/hs0202.102332Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33(2):572–577. doi:10.1161/hs0202.102332Matsubara M, Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis. 2005;178(1):57–66. doi:10.1016/j.atherosclerosis.2004.08.020Matsubara M, Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis. 2005;178(1):57–66. doi:10.1016/j.atherosclerosis.2004.08.020Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function — a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:79. doi:10.1186/1475-2840-10-79Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function — a crossover trial (AGENT). Cardiovasc Diabetol. 2011;10:79. doi:10.1186/1475-2840-10-79Yasu T, Kobayashi M, Mutoh A, Yamakawa K, Momomura S, Ueda S. Dihydropyridine calcium channel blockers inhibit non-esterified-fatty-acid-induced endothelial and rheological dysfunction. Clin Sci (Lond). 2013;125(5):247–255. doi:10.1042/CS20120311Yasu T, Kobayashi M, Mutoh A, Yamakawa K, Momomura S, Ueda S. Dihydropyridine calcium channel blockers inhibit non-esterified-fatty-acid-induced endothelial and rheological dysfunction. Clin Sci (Lond). 2013;125(5):247–255. doi:10.1042/CS20120311Okamura T, Tawa M, Geddawy A, Shimosato T, Iwasaki H, Shintaku H et al. Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. J Pharmacol Sci. 2014;124(1):76–85. doi:10.1254/jphs.13178fpOkamura T, Tawa M, Geddawy A, Shimosato T, Iwasaki H, Shintaku H et al. Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. J Pharmacol Sci. 2014;124(1):76–85. doi:10.1254/jphs.13178fpZhou MS, Tian R, Jaimes EA, Raij L. Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. Am J Hypertens. 2014;27(6):873–880. doi:10.1093/ajh/hpt272Zhou MS, Tian R, Jaimes EA, Raij L. Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. Am J Hypertens. 2014;27(6):873–880. doi:10.1093/ajh/hpt272Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-1Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-1Голованова Е. Д. Ремоделирование сосудов и вариабельность сердечного ритма при фармакотерапии артериальной гипертонии различными средствами. Рациональная фармакотерапия в кардиологии. 2008;4(1):62–66. doi:10.20996/1819-6446-2008-4-1-62-66Golovanova ED. Vascular remodeling and heart rate variability in pharmacotherapy of arterial hypertension by various means. Ratsionalnaya Farmakoterapiya v Kardiologii = Rational Pharmacotherapy in Cardiology. 2008;4(1):62–66. doi:10.20996/1819-6446-2008-4-1-62–66. In Russian.Кобалава Ж. Д., Котовская Ю. В., Маркова М. А., Виллевальде С. В. Высокое систолическое давление: акцент на эластические свойства артерий. КВТиП. 2006;5(6):10–16.Kobalava ZhD, Kotovskaya YuV, Markova MA, Villevalde SV. High systolic pressure: emphasis on the elastic properties of arteries. KBTiP. 2006;5(6):10–16. In Russian.

The authors declare that there are no conflicts of interest present.